Business Context and Reporting Period
Pyxis Oncology, Inc. filed this Form 8-K on August 23, 2023, reporting the completion of its previously announced strategic combination with Apexigen, Inc. The transaction was completed under the May 23, 2023 Agreement and Plan of Merger. Apexigen survived the merger as a wholly owned subsidiary of Pyxis Oncology.
Transaction and Key Financial Information
- Apexigen common stock was converted into Pyxis Oncology common stock at an exchange ratio of 0.1725 shares of Pyxis Oncology common stock for each Apexigen share, subject to rounding.
- Pyxis Oncology issued approximately 4,344,497 shares of common stock in the merger.
- Apexigen options, restricted stock units and warrants were assumed and converted into equivalent Pyxis Oncology awards or warrants, generally using the 0.1725 exchange ratio.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity or other operating financial metrics for the reporting period.
Material Changes Versus the Prior Comparable Period
The material change reported is the consummation of the Apexigen acquisition. The filing does not provide comparative financial statements or quantify the merger’s effect on Pyxis Oncology’s financial results, capital structure beyond the shares issued, cash position or operating expenses.
Governance, Outlook and Unusual Items
- The Pyxis Oncology board increased from six to seven members.
- Jakob Dupont, M.D., a former Apexigen director, was appointed as an independent Class III director effective at the merger closing. His term expires at the 2024 annual meeting.
- Dr. Dupont will receive compensation consistent with Pyxis Oncology’s other non-employee directors and entered into the company’s standard form of indemnification agreement.
- The filing contains no financial guidance, formal outlook or management projections.
- Financial statements for Apexigen and pro forma financial information were not included. Pyxis Oncology stated that it intends to file both by amendment within 71 calendar days after the Form 8-K filing deadline.
- Descriptions of merger agreement representations, warranties and covenants are contractual disclosures and should not be interpreted as independent statements of current fact or condition.
Investor Verification Items
- Review the subsequently filed Apexigen historical financial statements and pro forma financial information.
- Verify the final number of Pyxis Oncology shares outstanding after the merger, including converted options, restricted stock units and warrants.
- Assess the acquisition’s impact on cash usage, operating expenses, dilution and future financing requirements.
- Review the merger agreement, registration statement and related disclosures for transaction conditions, omitted schedules and contingent obligations.
- Monitor subsequent filings for clinical, regulatory, strategic or integration developments associated with Apexigen’s assets.